At Least Half Of All Kidney Transplant Recipients Benefit From Drug Level Testing To Prevent Organ Rejection

 23.08.2008 10:30   medicalnewstoday.com

Data presented at the 22nd International Congress of The Transplantation Society provides further direction to transplant doctors to test the immunosuppression drug levels of patients who are most at risk of rejecting their transplanted organ. The data, a follow-up analysis of the FDCC* study of 901 kidney transplant recipients, shows that the active component in CellCept, mycophenolic acid (MPA), should be measured in 'at risk'** patients.

World Transplantation